CXCR4 and breast carcinoma: These various patterns of selectivity seen in the jurkat-NefM1 and breast cancer MB-231 assays can be traced to differing profiles of intrinsic HIV-blocking potency in the MAGI assay and CXCR4 functional response but with some exceptions.